open access

Vol 73, No 5 (2022)
Original paper
Submitted: 2021-10-16
Accepted: 2022-02-06
Published online: 2022-09-05
Get Citation

Nuclear-targeted EGF receptor enhances proliferation and migration of human anaplastic thyroid cancer cells

Xudong Niu1, Jiaoling Chen2, Ningshun Ma, Ru Huang, Cong Tao, Qiang Dan, Yongpeng Fang
·
Pubmed: 36094870
·
Endokrynol Pol 2022;73(5):803-811.
Affiliations
  1. Internal Medicine Department, Yinchuan City Maternal and Child Health Hospital, Yinchuan city, Ningxia province, China
  2. Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou city, Guangdong Province, China

open access

Vol 73, No 5 (2022)
Original Paper
Submitted: 2021-10-16
Accepted: 2022-02-06
Published online: 2022-09-05

Abstract

Introduction: Epidermal growth factor (EGF) has various important physiological functions, which it exerts by binding to  the epidermal growth factor receptor (EGFR). Reports show that EGF expression is strongly correlated with the occurrence and development of many types of tumour. To date, however, the relationship between EGF/EGFR and the occurrence and development of thyroid carcinoma remains unclear.

Material and methods: In the current study, we investigated this phenomenon using human anaplastic thyroid carcinoma cell lines (SUN-80).

Results: The results indicated that EGF triggered the EGFR-mediated intracellular signalling pathway, including signal transducers and activators of transcription 1/3/5 (STAT1/3/5) and protein kinase B (AKT) in a time- and dose-dependent manner. In addition, results from EGF-induced EGFR internalization and co-localization analyses showed that clathrin, Rab5/7, and EEA1 play critical roles in the intracellular trafficking of EGF/EGFR. Interestingly, EGF triggered EGFR translocation into the nucleus, while nuclear-localized EGFR affected cell cycle distribution, thereby significantly promoting the ration of S phase. Overall, these findings indicated that nuclear EGFR exerts biological activity and physiological functions, including changing cell cycle, which in turn promotes proliferation and migration of SUN-80 cells.

Conclusion: These findings lay a foundation for further explorations seeking to understand the biological effects of the EGF/EGFR system on the occurrence and development of thyroid cancer.

Abstract

Introduction: Epidermal growth factor (EGF) has various important physiological functions, which it exerts by binding to  the epidermal growth factor receptor (EGFR). Reports show that EGF expression is strongly correlated with the occurrence and development of many types of tumour. To date, however, the relationship between EGF/EGFR and the occurrence and development of thyroid carcinoma remains unclear.

Material and methods: In the current study, we investigated this phenomenon using human anaplastic thyroid carcinoma cell lines (SUN-80).

Results: The results indicated that EGF triggered the EGFR-mediated intracellular signalling pathway, including signal transducers and activators of transcription 1/3/5 (STAT1/3/5) and protein kinase B (AKT) in a time- and dose-dependent manner. In addition, results from EGF-induced EGFR internalization and co-localization analyses showed that clathrin, Rab5/7, and EEA1 play critical roles in the intracellular trafficking of EGF/EGFR. Interestingly, EGF triggered EGFR translocation into the nucleus, while nuclear-localized EGFR affected cell cycle distribution, thereby significantly promoting the ration of S phase. Overall, these findings indicated that nuclear EGFR exerts biological activity and physiological functions, including changing cell cycle, which in turn promotes proliferation and migration of SUN-80 cells.

Conclusion: These findings lay a foundation for further explorations seeking to understand the biological effects of the EGF/EGFR system on the occurrence and development of thyroid cancer.

Get Citation

Keywords

cell behaviour; clathrin; EGF; EGFR; thyroid cancer

About this article
Title

Nuclear-targeted EGF receptor enhances proliferation and migration of human anaplastic thyroid cancer cells

Journal

Endokrynologia Polska

Issue

Vol 73, No 5 (2022)

Article type

Original paper

Pages

803-811

Published online

2022-09-05

Page views

4250

Article views/downloads

523

DOI

10.5603/EP.a2022.0048

Pubmed

36094870

Bibliographic record

Endokrynol Pol 2022;73(5):803-811.

Keywords

cell behaviour
clathrin
EGF
EGFR
thyroid cancer

Authors

Xudong Niu
Jiaoling Chen
Ningshun Ma
Ru Huang
Cong Tao
Qiang Dan
Yongpeng Fang

References (28)
  1. Biswas DK, Cruz AP, Gansberger E, et al. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000; 97(15): 8542–8547.
  2. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001; 3(9): 802–808.
  3. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, et al. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci U S A. 1986; 83(11): 3728–3732.
  4. Carpenter G, Cohen S, Cohen S, et al. Interaction of epidermal growth factor (EGF) with cultured fibroblasts. Adv Metab Disord. 1975; 8(4): 265–284.
  5. Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006; 91(9): 3662–3666.
  6. Lee DHo, Lee GK, Kong SY, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol. 2007; 60(8): 881–884.
  7. Vanlandingham PA, Ceresa BP. Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J Biol Chem. 2009; 284(18): 12110–12124.
  8. Lopez-Alcalá C, Alvarez-Moya B, Villalonga P, et al. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem. 2008; 283(16): 10621–10631.
  9. Gosney JA, Wilkey DW, Merchant ML, et al. Proteomics reveals novel protein associations with early endosomes in an epidermal growth factor-dependent manner. J Biol Chem. 2018; 293(16): 5895–5908.
  10. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009; 78: 857–902.
  11. Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol. 2010; 3(1): 37–52.
  12. Lo HW, Hung MC, Lo HW, et al. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer. 2006; 94(2): 184–188.
  13. Yarden Y, Shilo BZ. SnapShot: EGFR signaling pathway. Cell. 2007; 131(5): 1018.
  14. Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007; 67(19): 9066–9076.
  15. Lo HW, Cao X, Zhu Hu, et al. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008; 14(19): 6042–6054.
  16. Cordero JB, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem. 2002; 277(41): 38965–38971.
  17. de la Iglesia N, Konopka G, Puram SV, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008; 22(4): 449–462.
  18. Xia W, Wei Y, Du Yi, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog. 2009; 48(7): 610–617.
  19. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005; 11(16): 5856–5862.
  20. Wang YN, Hung MC, Wang YN, et al. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene. 2010; 29(28): 3997–4006.
  21. Emamian ES. AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012; 5: 33.
  22. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011; 12(8): 517–533.
  23. Kaksonen M, Toret CP, Drubin DG. Harnessing actin dynamics for clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2006; 7(6): 404–414.
  24. Sigismund S, Argenzio E, Tosoni D, et al. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008; 15(2): 209–219.
  25. Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005; 6(2): 112–126.
  26. Orth JD, Krueger EW, Weller SG, et al. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res. 2006; 66(7): 3603–3610.
  27. Liu L, Shao X, Gao W, et al. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 2012; 279(20): 3800–3812.
  28. Andl CD, Mizushima T, Nakagawa H, et al. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003; 278(3): 1824–1830.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl